BDSI:NSD-BioDelivery Sciences International, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.83

Change

+0.07 (+1.86)%

Market Cap

USD 0.37B

Volume

0.41M

Avg Analyst Target

USD 5.88 (+53.39%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-6.99 (-1.98%)

USD141.98B 237.00 190.09
BNTX BioNTech SE

+11.86 (+3.61%)

USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

+2.52 (+0.44%)

USD61.22B 16.36 12.83
VRTX Vertex Pharmaceuticals Incorpo..

-3.26 (-1.62%)

USD52.23B 26.58 13.36
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab A/S

+0.12 (+0.27%)

USD29.62B 33.28 3.77
BGNE BeiGene, Ltd

+10.83 (+3.42%)

USD29.25B N/A N/A
SGEN Seagen Inc

+0.85 (+0.55%)

USD27.91B 47.87 38.34
RPRX Royalty Pharma plc

-0.99 (-2.59%)

USD23.19B 31.49 13.92
ALNY Alnylam Pharmaceuticals, Inc

-0.98 (-0.55%)

USD21.03B N/A N/A

ETFs Containing BDSI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.81% 55% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.81% 55% F 25% F
Trailing 12 Months  
Capital Gain -13.93% 47% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.93% 47% F 16% F
Trailing 5 Years  
Capital Gain 55.06% 66% D 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.06% 66% D 51% F
Average Annual (5 Year Horizon)  
Capital Gain 22.67% 56% F 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.67% 55% F 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 44.02% 70% C- 41% F
Risk Adjusted Return 51.50% 77% C+ 70% C-
Market Capitalization 0.37B 54% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.67 37% F 54% F
Price/Book Ratio 3.40 49% F 42% F
Price / Cash Flow Ratio 14.83 6% F 29% F
EV/EBITDA 7.94 37% F 75% C
Management Effectiveness  
Return on Equity 28.02% 97% A+ 92% A-
Return on Invested Capital 20.78% 91% A- 90% A-
Return on Assets 11.28% 97% A+ 95% A
Debt to Equity Ratio 72.48% 13% F 29% F
Technical Ratios  
Short Ratio 3.42 52% F 39% F
Short Percent 2.65% 79% C+ 55% F
Beta 0.72 79% C+ 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.